<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postpartum thyroiditis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postpartum thyroiditis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postpartum thyroiditis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth D Burman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Postpartum thyroiditis is a destructive thyroiditis induced by an autoimmune mechanism within one year after parturition. Postpartum thyroiditis can also occur after spontaneous or induced abortion [<a href="#rid1">1</a>]. It usually presents in one of three ways  (<a class="graphic graphic_figure graphicRef75131" href="/z/d/graphic/75131.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Transient hyperthyroidism alone</p><p class="bulletIndent1"><span class="glyph">●</span>Transient hypothyroidism alone</p><p class="bulletIndent1"><span class="glyph">●</span>Transient hyperthyroidism followed by hypothyroidism and then recovery</p><p></p><p>The clinical manifestations, diagnosis, and treatment of postpartum thyroiditis are reviewed here. Other forms of thyroiditis and the diagnosis and management of thyroid dysfunction during pregnancy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">"Overview of thyroiditis"</a> and  <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/16609.html" rel="external">"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE AND NATURAL HISTORY</span><span class="headingEndMark"> — </span>The reported prevalence of postpartum thyroiditis varies globally and ranges from 1 to 17 percent [<a href="#rid2">2-5</a>]. In systematic reviews of prospective studies, the mean prevalence in the general population of women was approximately 7 to 8 percent [<a href="#rid2">2,3</a>]. Higher rates, up to 25 percent, have been reported in women with type 1 diabetes mellitus [<a href="#rid2">2,3</a>], and the highest rates occur among women with a prior history of postpartum thyroiditis (pooled prevalence 42 percent) and in women with positive antithyroid peroxidase antibodies who had normal thyroid function during pregnancy (40 to 60 percent compared with 0 to 5 percent of women without antibodies) [<a href="#rid2">2</a>]. Postpartum thyroid dysfunction can occur in people already taking thyroid hormone replacement for hypothyroidism antedating pregnancy (eg, goitrous Hashimoto's thyroiditis), if they have some remaining thyroid tissue capable of producing thyroid hormone [<a href="#rid6">6</a>].</p><p>Most patients recover and are euthyroid within one year postpartum. However, some individuals never recover from the initial hypothyroid phase and have permanent hypothyroidism or goiter [<a href="#rid7">7-11</a>]. In addition, people with reversible hypothyroidism are at increased risk for developing permanent hypothyroidism in the future [<a href="#rid4">4,12,13</a>]. Studies evaluating the likelihood of a woman developing permanent hypothyroidism report a wide incidence (4 to 54 percent), but the best estimate is approximately 20 to 40 percent within 3 to 12 years [<a href="#rid4">4</a>]. As an example, in a study of 45 patients followed for eight years, 14 (31 percent) developed permanent hypothyroidism [<a href="#rid14">14</a>]. Although there are no definitive characteristics that can assist in predicting which patients will develop hypothyroidism, progression to permanent hypothyroidism may be related to higher initial TSH concentrations and the antithyroid peroxidase antibody titer [<a href="#rid4">4,9,13,14</a>], maternal age, and female sex of the infant [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Postpartum thyroiditis, like painless thyroiditis, is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis). The pathologic findings in the two disorders are similar (see <a class="local">'Pathology'</a> below), and both are associated with particular human leukocyte antigen (HLA)-B and HLA-D haplotypes, suggesting that inherited risk factors are important [<a href="#rid15">15</a>].</p><p>Individuals destined to develop postpartum thyroiditis usually have high serum antithyroid peroxidase antibody concentrations early in pregnancy, which decline later (as immunologic tolerance increases during pregnancy) and then rise again after delivery [<a href="#rid16">16</a>]. Thus, people destined to develop postpartum thyroiditis have subclinical thyroid autoimmune disease early in pregnancy and soon after it.</p><p>Whatever factors initiate postpartum thyroiditis, the resulting thyroid inflammation damages thyroid follicles and activates proteolysis of the thyroglobulin stored within the follicles. The result is unregulated release of large amounts of thyroxine (T4) and triiodothyronine (T3) into the circulation and subsequent hyperthyroidism. This state lasts only until the stores of thyroglobulin are exhausted because new hormone synthesis ceases, not only because of damage to the thyroid follicular cells but also because of inhibition of thyroid-stimulating hormone (TSH) secretion by the increased serum T4 and T3 concentrations. As the inflammation subsides, the thyroid follicles regenerate and thyroid hormone synthesis and secretion resume  (<a class="graphic graphic_figure graphicRef75131" href="/z/d/graphic/75131.html" rel="external">figure 1</a>). There may be a transient period of hypothyroidism and increased TSH secretion before thyroid secretion becomes normal again.</p><p class="headingAnchor" id="H17344418"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H6"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The presentation of postpartum thyroiditis can be identical to painless thyroiditis, but the course of postpartum thyroiditis may be more variable. This apparent difference may reflect the greater ease of studying postpartum women prospectively than women in the general population. (See  <a class="medical medical_review" href="/z/d/html/7830.html" rel="external">"Painless thyroiditis"</a>.)</p><p>Approximately 20 to 30 percent of women with postpartum thyroiditis have the characteristic sequence of hyperthyroidism, which usually begins one to four months after delivery and lasts two to eight weeks, followed by hypothyroidism, which lasts from approximately two weeks to six months, and then recovery  (<a class="graphic graphic_figure graphicRef75131" href="/z/d/graphic/75131.html" rel="external">figure 1</a>) [<a href="#rid4">4,17</a>]. However, 20 to 40 percent have only hyperthyroidism, and the remaining 40 to 50 percent have only hypothyroidism, which begins two to six months after delivery. Some women do not restore normal endogenous thyroid function after the initial episode of hypothyroidism [<a href="#rid7">7,8</a>].</p><p>The symptoms and signs of hyperthyroidism, when present, are typically mild and consist mainly of fatigue, weight loss, palpitations, heat intolerance, anxiety, irritability, tachycardia, and tremor. Similarly, hypothyroidism is also usually mild, leading to lack of energy, cold intolerance, constipation, sluggishness, and dry skin [<a href="#rid4">4</a>] (see  <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a>). The symptoms that occur during the hyperthyroid phase are often only apparent retrospectively when the hypothyroid phase is diagnosed. Many of the symptoms of postpartum thyroiditis are inadvertently attributed to breastfeeding or the stresses of having a newborn child, as many postpartum individuals with normal thyroid function tests have fatigue, loss of energy, and anxiety, making the recognition of thyroid dysfunction difficult.</p><p>While it has been suggested that hypothyroidism may be associated with or aggravate postpartum depression [<a href="#rid18">18,19</a>], in subsequent prospective studies there was no association despite a high prevalence of postpartum thyroid dysfunction (11 to 12 percent) and postpartum depression (2 to 9 percent) [<a href="#rid20">20,21</a>].</p><p>Most individuals with postpartum thyroiditis have a mildly enlarged, diffuse, nontender thyroid gland when their thyroid function is abnormal, which disappears with recovery. In some people, however, goiter is the presenting complaint.</p><p>In addition to the usual clinical consequences of thyroid dysfunction, postpartum hypothyroidism may decrease milk volume [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>The biochemical findings in patients with postpartum thyroiditis are similar to those of painless thyroiditis: high or high-normal serum free T4 and T3 concentrations and low serum TSH concentrations during the hyperthyroid phase, which may be overt or subclinical. During the hypothyroid phase, serum free T4 concentrations are low or low-normal and serum TSH concentrations are high, consistent with either overt or subclinical hypothyroidism (see  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>). In those individuals with hyperthyroidism followed by hypothyroidism, serum T4 concentrations may be low for several days to weeks before serum TSH concentrations rise above the normal range, because of prolonged TSH suppression that had occurred during the hyperthyroid phase.</p><p>Serum antithyroid peroxidase antibody concentrations are high in 60 to 85 percent of women with postpartum thyroiditis [<a href="#rid10">10,17,23</a>] and are highest during the hypothyroid phase or soon thereafter. Routine laboratory studies (eg, complete blood count [CBC], comprehensive metabolic panel [CMP]) are usually normal, but some women have a slightly increased erythrocyte sedimentation rate and/or C-reactive protein. No consistent abnormalities in numbers or types of peripheral blood (or intrathyroidal) T lymphocytes have been reported.</p><p class="headingAnchor" id="H564660"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Thyroid biopsies in women with postpartum thyroiditis show lymphocytic infiltration, with occasional germinal centers, and disruption and collapse of thyroid follicles (lymphocytic thyroiditis) [<a href="#rid10">10,24</a>]. Fine-needle aspiration biopsies reveal lymphocytes, thyroid follicular cells, and masses of colloid. During recovery, lymphocytic infiltration is still seen and there may be some fibrosis, but the thyroid follicles are more normal. Thyroid aspirations are not typically required unless there is a specific indication, such as detection of a thyroid nodule.</p><p class="headingAnchor" id="H8356863"><span class="h2">Radioiodine uptake</span><span class="headingEndMark"> — </span>During the hyperthyroid phase of postpartum thyroiditis, values for thyroid radioiodine uptake are low, usually less than 1 percent, compared with high values in Graves' hyperthyroidism. However, breastfeeding is a strong relative contraindication to radioiodine (or technetium) administration, and must be suspended for at least several days until the breast milk is no longer radioactive. Because the hyperthyroid phase of postpartum thyroiditis is often only apparent retrospectively when the hypothyroid phase is diagnosed, radioiodine uptake and scanning is not usually necessary. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H17344246"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of postpartum thyroiditis is based upon clinical manifestations and thyroid function tests (TSH, free T4). Clinicians caring for postpartum individuals should be alert to the possibility of postpartum thyroid dysfunction as a cause of many symptoms during this period.</p><p class="headingAnchor" id="H23963773"><span class="h2">Thyroid function tests</span><span class="headingEndMark"> — </span>Routine measurement of thyroid function tests in the postpartum period in patients without relevant specific signs or symptoms is not usually required. However, laboratory assessment of thyroid function should be performed at three and six months postpartum in people at high risk for developing postpartum thyroiditis (see <a class="local">'Screening'</a> below), including those with:</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>A history of postpartum thyroiditis after a previous pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>A history of high serum antithyroid peroxidase antibodies prior to pregnancy</p><p></p><p>And at the time of symptoms, in people with:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations of postpartum thyroiditis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postpartum depression (because of the potential association between postpartum depression and postpartum hypothyroidism and because hypothyroidism is a reversible cause of depression)</p><p></p><p>We typically measure TSH and free T4, rather than TSH alone, because thyroid function tests may fluctuate during the course of postpartum thyroiditis, and changes in TSH concentrations lag behind changes in serum free T4. If the TSH is low, T3 should also be measured.</p><p class="headingAnchor" id="H23963779"><span class="h2">Additional evaluation</span><span class="headingEndMark"> — </span>Additional evaluation depends upon whether a patient presents with hypothyroidism or hyperthyroidism.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum hypothyroidism</strong> – For patients presenting with postpartum hypothyroidism, assessment of antithyroid peroxidase antibodies may be helpful in confirming postpartum thyroiditis and also in helping to predict the future course of the disease. (See <a class="local">'Prevalence and natural history'</a> above and <a class="local">'Duration of thyroid hormone therapy'</a> below.)</p><p></p><p class="bulletIndent1">When antithyroid peroxidase antibodies are not measured, the diagnosis of postpartum thyroiditis can be confirmed if hypothyroidism resolves within several weeks without thyroid hormone replacement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum hyperthyroidism</strong> – For patients presenting with hyperthyroidism, further evaluation may be needed to differentiate postpartum thyroiditis from Graves' disease  (<a class="graphic graphic_algorithm graphicRef133239" href="/z/d/graphic/133239.html" rel="external">algorithm 1</a>). For patients with clinical manifestations of Graves' disease (ophthalmopathy), with persistent hyperthyroidism (&gt;1 month), or with severe hyperthyroidism (markedly elevated T3&gt;T4), we typically obtain serum thyrotropin receptor antibodies (TRAb, measured by TSI or TBII [TBI] ) to confirm the diagnosis of Graves' disease. Thyroid ultrasound with Doppler flow may also be useful to distinguish Graves' disease (high blood flow) from the hyperthyroid phase of painless or postpartum thyroiditis (low blood flow) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">For individuals without clinical manifestations of Graves' disease or severe or persistent hyperthyroidism, we do not obtain additional tests, but we repeat thyroid function tests (TSH, free T4, T3) in three to four weeks. By that time, most patients with postpartum thyroiditis will have improved, whereas those with Graves' hyperthyroidism will usually be unchanged or worse.</p><p></p><p class="bulletIndent1">Radionuclide imaging is contraindicated in pregnant people and in those who are actively or recently breast feeding (breastfeeding must be suspended for at least several days until the breast milk is no longer radioactive). (See  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Determining the etiology'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H2060224"><span class="h2">Hyperthyroid phase</span><span class="headingEndMark"> — </span>For patients who present with clinical and/or laboratory (high or high-normal serum free T4 and T3 and low serum TSH) manifestations of hyperthyroidism, it may be difficult to distinguish the hyperthyroid phase of postpartum thyroiditis from Graves' hyperthyroidism, which can also begin during the postpartum period, either as recurrent or new-onset hyperthyroidism  (<a class="graphic graphic_algorithm graphicRef133239" href="/z/d/graphic/133239.html" rel="external">algorithm 1</a>) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Determining the etiology'</a>.)</p><p>The timing of onset, severity of symptoms, and pattern of thyroid function tests may suggest one etiology over the other, but there is significant overlap [<a href="#rid25">25,26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In general, onset of hyperthyroidism within three months of delivery is more suggestive of postpartum thyroiditis, whereas onset after six months is more likely Graves' disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The primary clinical differences between postpartum thyroiditis and Graves' hyperthyroidism are that hyperthyroidism in postpartum thyroiditis is usually mild (both clinically and biochemically), thyroid enlargement is minimal, and Graves' ophthalmopathy is absent. In contrast, with Graves' hyperthyroidism, patients are usually more symptomatic, have more thyroid enlargement, and may have ophthalmopathy or pretibial myxedema. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Graves' hyperthyroidism have higher serum thyroid hormone concentrations. In Graves' disease, the serum T3 is typically elevated (in comparison with the upper limits of normal) to a greater degree than is the free T4, whereas the opposite is true in postpartum thyroiditis. Thus, a high T3-to-T4 ratio (the value of which is assay and unit dependent) suggests Graves' disease, while a ratio close to that of euthyroid patients suggests a destructive thyroiditis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum thyrotropin receptor antibody (TRAb, measured by TSI or TBII [TBI] assays) levels are typically elevated in Graves' hyperthyroidism but not in postpartum thyroiditis.</p><p></p><p>In some patients, particularly those without new-onset ophthalmopathy, the distinction may nevertheless be difficult. In such cases, further evaluation may be needed. (See <a class="local">'Additional evaluation'</a> above.)</p><p class="headingAnchor" id="H2060231"><span class="h2">Hypothyroid phase</span><span class="headingEndMark"> — </span>For patients who present with clinical manifestations of hypothyroidism, the hypothyroid phase of postpartum thyroiditis (low or low-normal serum free T4 and high TSH) must be differentiated from lymphocytic hypophysitis, which also may occur during late pregnancy or the postpartum period. Lymphocytic hypophysitis may cause deficiency of TSH, as well as one or more additional pituitary hormones, including corticotropin (ACTH) [<a href="#rid27">27,28</a>]. Spontaneous recovery of pituitary gland function or, alternatively, persistent and chronic hypopituitarism may occur [<a href="#rid29">29</a>]. In lymphocytic hypophysitis, the serum TSH is expected to be inappropriately normal or low in the context of a low free T4, whereas in hypothyroidism with postpartum thyroiditis, the TSH should be elevated in conjunction with a decreased free T4. (See  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Hypophysitis'</a>.)</p><p>Postpartum thyroiditis is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis) (see <a class="local">'Pathogenesis'</a> above). It is not necessary to routinely measure antithyroid peroxidase antibodies in patients with postpartum hypothyroidism. People who do not recover from the initial hypothyroid phase within one year postpartum likely have chronic autoimmune thyroiditis and permanent hypothyroidism, and in these individuals, measurement of antithyroid peroxidase antibodies should be considered.</p><p class="headingAnchor" id="H522339"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>The frequency of postpartum thyroiditis raises the question of whether screening is indicated [<a href="#rid30">30</a>]. This could be done by periodic clinical evaluation or serum TSH assay after delivery. Alternatively, serum antithyroid peroxidase antibodies could be measured, either early in pregnancy or soon after delivery. High antibody concentrations at these times predict (but not with certainty) the later development of postpartum thyroiditis, and low concentrations make it very unlikely [<a href="#rid12">12,16,17,31</a>].</p><p>We agree with the Endocrine Society clinical guidelines that there is insufficient evidence to support a recommendation for screening all pregnant people for postpartum thyroiditis [<a href="#rid3">3</a>]. However, individuals at highest risk for developing postpartum thyroiditis (eg, antithyroid peroxidase antibody positive, type 1 diabetes, previous episode of postpartum thyroiditis) should have a serum TSH measurement at three and six months postpartum [<a href="#rid3">3</a>]. If the TSH level is abnormal, it should be repeated soon thereafter along with a free T4 level and T3 (T3 measurement indicated if TSH is low), within one to two weeks.</p><p class="headingAnchor" id="H9"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>There are no established therapies to prevent the occurrence of postpartum thyroiditis in patients with antithyroid peroxidase antibodies.</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) or iodine to pregnant people with high serum antithyroid antibody concentrations did not prevent postpartum thyroiditis [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">Selenium</a> supplementation, however, may decrease inflammatory activity in pregnant people with autoimmune hypothyroidism [<a href="#rid34">34</a>] and may reduce the risk of postpartum thyroiditis in people who are positive for thyroid peroxidase (TPO) antibodies. This was illustrated in a trial of 151 TPO-positive women randomly assigned to receive selenium (200 mcg daily) or placebo (beginning at approximately the 12<sup>th</sup> week of gestation). The prevalence of postpartum thyroiditis was significantly lower in the selenium group (22 of 77 women [29 percent] versus 36 of 74 [49 percent]) [<a href="#rid35">35</a>]. The routine clinical application of this supplementation requires further study, especially since selenium deficiency may have existed in this cohort from Italy.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>In the absence of randomized trials comparing different treatment strategies, treatment recommendations are based upon observational studies and clinical experience [<a href="#rid3">3,7-9,14</a>].</p><p class="headingAnchor" id="H8727094"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Our approach, which is similar to that of the Endocrine Society [<a href="#rid3">3</a>] and the American Thyroid Association (ATA) [<a href="#rid5">5</a>], is outlined below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic with mild thyroid function test abnormalities</strong> – The majority of people with postpartum thyroiditis need no treatment during either the hyperthyroid or the hypothyroid phases of their illness. Asymptomatic individuals who have a mildly elevated serum TSH (between the upper limit of the normal range and 10 mU/L) and who are not planning another pregnancy also do not necessarily require intervention, although individual decisions should be made in the clinical and laboratory context. </p><p></p><p class="bulletIndent1">Thyroid function tests (TSH, free T4, and if hyperthyroid, T3) should be monitored every four to eight weeks to confirm resolution of biochemical abnormalities or to detect the development of more severe hypothyroidism, indicating possible permanent hypothyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic hyperthyroidism</strong> – Patients who have bothersome symptoms of hyperthyroidism can be treated with 40 to 120 mg <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> or 25 to 50 mg <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> or <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> daily until their serum T3 and serum free T4 concentrations are normal. During breastfeeding, propranolol is preferred because, due to high plasma protein binding, it is not concentrated in breast milk as much as other beta blockers, such as atenolol [<a href="#rid36">36</a>]. Atenolol is not used during breastfeeding [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">There is <strong>no role</strong> for antithyroid drugs (ie, <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>) or radioiodine in the treatment of the hyperthyroid phase of postpartum thyroiditis because the synthesis of T4 and T3 is decreased, not increased as in most other disorders causing hyperthyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic hypothyroidism or TSH ≥10 mU/L – </strong>Patients with symptomatic hypothyroidism should be treated with T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) irrespective of the degree of TSH elevation. In asymptomatic individuals, we prefer to treat when the TSH is ≥10 mU/L. While most patients will become euthyroid within a few months, some will have persistent hypothyroidism, which may have a negative effect on lactation, subsequent pregnancies, and, if longstanding, may increase the risk of cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Cardiovascular disease'</a> and  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Candidates for T4 replacement'</a>.) </p><p></p><p class="bulletIndent1">The initial dose is typically approximately 50 to 100 mcg/day, although requirements may vary. Some clinicians begin full-dose <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> (1.6 mcg/kg/day). As long as TSH is measured six weeks later and appropriate adjustment in the levothyroxine dose is made, either approach is reasonable in this relatively young population.</p><p></p><p class="bulletIndent1">When T4 is instituted in these circumstances, the goal is a normal TSH.</p><p></p><p class="headingAnchor" id="H8726888"><span class="h2">Duration of thyroid hormone therapy</span><span class="headingEndMark"> — </span>The duration of thyroid hormone therapy, once initiated, is uncertain. Since postpartum thyroid dysfunction is often transient, many experts favor tapering T4 after 6 to 12 months, unless the person is pregnant, attempting pregnancy, or breastfeeding [<a href="#rid4">4</a>]. Because there are no prospective, controlled data confirming the best approach, the decision to withdraw thyroid hormone therapy should be based upon individual patient characteristics and preferences.</p><p>We favor withdrawing thyroid hormone as a clinical trial in most people, except as noted above, after 6 to 12 months of therapy. In patients at high risk for permanent hypothyroidism or patients who are reluctant to stop hormone fearing a return of hypothyroid symptoms, the dose could be halved for six weeks and, if the TSH does not rise, stopped with reassessment of thyroid function after an additional six weeks.</p><p>Up to 30 percent of individuals never recover from the initial hypothyroid phase, and a rising TSH level during T4 weaning is indicative of persistent hypothyroidism, requiring long term T4. In some reports, high titers of antithyroid peroxidase antibodies and the severity of the initial hypothyroid phase predicted the development of permanent hypothyroidism [<a href="#rid7">7,13,14,38</a>]. Thus, in patients with very elevated initial TSH values (&gt;50 or 100 mU/L), an alternative approach is to continue thyroid hormone indefinitely.</p><p class="headingAnchor" id="H8726894"><span class="h2">Long-term follow-up</span><span class="headingEndMark"> — </span>In people with a history of postpartum thyroiditis, recurrence is likely after future pregnancies, and there is substantial risk for the later development of hypothyroidism or goiter. Such patients should be counseled regarding the possible development of symptoms. After full recovery from postpartum thyroiditis, we measure serum TSH levels annually, particularly within 5 to 10 years after the initial diagnosis [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3603828871"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112934.html" rel="external">"Society guideline links: Thyroid disease and pregnancy"</a>.)</p><p class="headingAnchor" id="H13598856"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/85801.html" rel="external">"Patient education: Thyroiditis after pregnancy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H521341"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Approximately 20 to 30 percent of people with postpartum thyroiditis have the characteristic sequence of hyperthyroidism, which usually begins one to four months after delivery and lasts two to eight weeks, followed by hypothyroidism, which also lasts from approximately two weeks to six months, and then recovery  (<a class="graphic graphic_figure graphicRef75131" href="/z/d/graphic/75131.html" rel="external">figure 1</a>). Some individuals have only hyperthyroidism or only hypothyroidism. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">The symptoms and signs of hyperthyroidism, when present, are typically mild and consist mainly of fatigue, weight loss, palpitations, heat intolerance, anxiety, irritability, tachycardia, and tremor. Similarly, hypothyroidism is also usually mild, leading to lack of energy, cold intolerance, constipation, sluggishness, and dry skin.</p><p></p><p class="bulletIndent1">The biochemical findings depend upon the phase of postpartum thyroiditis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperthyroid phase – High or high-normal serum free thyroxine (T4) and triiodothyronine (T3) and low serum thyroid-stimulating hormone (TSH)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypothyroid phase – Low or low-normal serum free T4 and high serum TSH </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of postpartum thyroiditis is based upon clinical manifestations and thyroid function tests. In patients with symptoms or signs of hyperthyroidism or hypothyroidism in the postpartum period, we measure TSH and free T4, rather than TSH alone. Thyroid function tests may fluctuate during the course of postpartum thyroiditis, and changes in TSH concentrations lag behind changes in serum free T4. If the TSH is low, T3 should also be measured. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Thyroid function tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients presenting with postpartum hypothyroidism, assessment of antithyroid peroxidase antibodies may be helpful in confirming postpartum thyroiditis and also in helping to predict the future course of the disease. (See <a class="local">'Additional evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients presenting with postpartum hyperthyroidism, further evaluation may be needed to differentiate postpartum thyroiditis from Graves' disease  (<a class="graphic graphic_algorithm graphicRef133239" href="/z/d/graphic/133239.html" rel="external">algorithm 1</a>). When there are clinical manifestations of Graves' disease (ophthalmopathy), persistent hyperthyroidism (&gt;1 month), or severe hyperthyroidism (markedly elevated T3&gt;T4), we typically obtain serum thyrotropin receptor antibodies (TRAb, measured by TSI or TBII [TBI]) to confirm the diagnosis of Graves' disease. (See <a class="local">'Additional evaluation'</a> above.)</p><p></p><p class="bulletIndent2">In the absence of these clinical manifestations, we do not obtain additional tests, but we repeat thyroid function tests (TSH, free T4, T3) in three to four weeks. By that time, most patients with postpartum thyroiditis will have improved, whereas those with Graves' hyperthyroidism will usually be unchanged or worse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – For individuals at high risk for developing postpartum thyroiditis (eg, previously known to be thyroid peroxidase [TPO] antibody positive, type 1 diabetes, prior history of postpartum thyroiditis), we suggest screening for postpartum thyroiditis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically measure a TSH level three and six months postpartum. If the TSH level is abnormal, it should be repeated along with a free T4 level and T3 (if TSH is low), within one to two weeks. (See <a class="local">'Screening'</a> above and <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperthyroid phase</strong> – Most patients with postpartum thyroiditis do not require any treatment. Thyroid tests should be repeated in four to eight weeks to confirm resolution of hyperthyroidism. Beta blockers may be useful to relieve bothersome palpitations or tremulousness in symptomatic patients. If breastfeeding, we prefer <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> because it has the lowest transfer into milk. There is <strong>no role</strong> for antithyroid drugs (ie, <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>) or radioiodine in the treatment of the hyperthyroid phase of postpartum thyroiditis. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Control of symptoms'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypothyroid phase</strong> – Symptomatic patients with an elevated TSH above the normal range require treatment with T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>). For asymptomatic individuals with a TSH level ≥10 mU/L, we also suggest T4 replacement (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We do not routinely treat asymptomatic individuals with TSH levels below 10 mU/L. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – Since postpartum thyroid dysfunction is often transient, we favor weaning T4 after 6 to 12 months, unless the person is pregnant, attempting pregnancy, or breastfeeding. The dose can be halved with assessment of thyroid function (TSH, free T4) six weeks later, and, if the TSH does not rise, stopped with reassessment of thyroid function after an additional six weeks. (See <a class="local">'Duration of thyroid hormone therapy'</a> above.)</p><p></p><p class="bulletIndent1">Most patients recover and are euthyroid within one year postpartum. Up to 30 percent of individuals never recover from the initial hypothyroid phase and have permanent hypothyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Individuals with reversible hypothyroidism are also at increased risk for developing permanent hypothyroidism in the future and, therefore, require yearly monitoring of TSH. (See <a class="local">'Long-term follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marqusee E, Hill JA, Mandel SJ. Thyroiditis after pregnancy loss. J Clin Endocrinol Metab 1997; 82:2455.</a></li><li><a class="nounderline abstract_t">Nicholson WK, Robinson KA, Smallridge RC, et al. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid 2006; 16:573.</a></li><li><a class="nounderline abstract_t">De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543.</a></li><li><a class="nounderline abstract_t">Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab 2012; 97:334.</a></li><li><a class="nounderline abstract_t">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27:315.</a></li><li><a class="nounderline abstract_t">Caixàs A, Albareda M, García-Patterson A, et al. Postpartum thyroiditis in women with hypothyroidism antedating pregnancy? J Clin Endocrinol Metab 1999; 84:4000.</a></li><li><a class="nounderline abstract_t">Azizi F. The occurrence of permanent thyroid failure in patients with subclinical postpartum thyroiditis. Eur J Endocrinol 2005; 153:367.</a></li><li><a class="nounderline abstract_t">Tachi J, Amino N, Tamaki H, et al. Long term follow-up and HLA association in patients with postpartum hypothyroidism. J Clin Endocrinol Metab 1988; 66:480.</a></li><li><a class="nounderline abstract_t">Othman S, Phillips DI, Parkes AB, et al. A long-term follow-up of postpartum thyroiditis. Clin Endocrinol (Oxf) 1990; 32:559.</a></li><li><a class="nounderline abstract_t">Nikolai TF, Turney SL, Roberts RC. Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up. Arch Intern Med 1987; 147:221.</a></li><li><a class="nounderline abstract_t">Stagnaro-Green A, Schwartz A, Gismondi R, et al. High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab 2011; 96:652.</a></li><li><a class="nounderline abstract_t">Lazarus JH, Ammari F, Oretti R, et al. Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract 1997; 47:305.</a></li><li><a class="nounderline abstract_t">Stuckey BG, Kent GN, Ward LC, et al. Postpartum thyroid dysfunction and the long-term risk of hypothyroidism: results from a 12-year follow-up study of women with and without postpartum thyroid dysfunction. Clin Endocrinol (Oxf) 2010; 73:389.</a></li><li><a class="nounderline abstract_t">Lucas A, Pizarro E, Granada ML, et al. Postpartum thyroiditis: long-term follow-up. Thyroid 2005; 15:1177.</a></li><li><a class="nounderline abstract_t">Kologlu M, Fung H, Darke C, et al. Postpartum thyroid dysfunction and HLA status. Eur J Clin Invest 1990; 20:56.</a></li><li><a class="nounderline abstract_t">Stagnaro-Green A, Roman SH, Cobin RH, et al. A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol Metab 1992; 74:645.</a></li><li><a class="nounderline abstract_t">Lazarus JH, Hall R, Othman S, et al. The clinical spectrum of postpartum thyroid disease. QJM 1996; 89:429.</a></li><li><a class="nounderline abstract_t">Harris B, Othman S, Davies JA, et al. Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ 1992; 305:152.</a></li><li><a class="nounderline abstract_t">Lazarus JH, Othman S. Thyroid disease in relation to pregnancy. Clin Endocrinol (Oxf) 1991; 34:91.</a></li><li><a class="nounderline abstract_t">Kent GN, Stuckey BG, Allen JR, et al. Postpartum thyroid dysfunction: clinical assessment and relationship to psychiatric affective morbidity. Clin Endocrinol (Oxf) 1999; 51:429.</a></li><li><a class="nounderline abstract_t">Lucas A, Pizarro E, Granada ML, et al. Postpartum thyroid dysfunction and postpartum depression: are they two linked disorders? Clin Endocrinol (Oxf) 2001; 55:809.</a></li><li><a class="nounderline abstract_t">Miyake A, Tahara M, Koike K, Tanizawa O. Decrease in neonatal suckled milk volume in diabetic women. Eur J Obstet Gynecol Reprod Biol 1989; 33:49.</a></li><li><a class="nounderline abstract_t">Gerstein HC. How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med 1990; 150:1397.</a></li><li><a class="nounderline abstract_t">Mizukami Y, Michigishi T, Nonomura A, et al. Postpartum thyroiditis. A clinical, histologic, and immunopathologic study of 15 cases. Am J Clin Pathol 1993; 100:200.</a></li><li><a class="nounderline abstract_t">Ide A, Amino N, Kang S, et al. Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. Thyroid 2014; 24:1027.</a></li><li><a class="nounderline abstract_t">Izumi Y, Hidaka Y, Tada H, et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 2002; 57:51.</a></li><li><a class="nounderline abstract_t">Patel MC, Guneratne N, Haq N, et al. Peripartum hypopituitarism and lymphocytic hypophysitis. QJM 1995; 88:571.</a></li><li><a class="nounderline abstract_t">Landek-Salgado MA, Gutenberg A, Lupi I, et al. Pregnancy, postpartum autoimmune thyroiditis, and autoimmune hypophysitis: intimate relationships. Autoimmun Rev 2010; 9:153.</a></li><li><a class="nounderline abstract_t">Unlühizarci K, Bayram F, Colak R, et al. Distinct radiological and clinical appearance of lymphocytic hypophysitis. J Clin Endocrinol Metab 2001; 86:1861.</a></li><li><a class="nounderline abstract_t">Amino N, Tada H, Hidaka Y, et al. Therapeutic controversy: Screening for postpartum thyroiditis. J Clin Endocrinol Metab 1999; 84:1813.</a></li><li><a class="nounderline abstract_t">Premawardhana LD, Parkes AB, John R, et al. Thyroid peroxidase antibodies in early pregnancy: utility for prediction of postpartum thyroid dysfunction and implications for screening. Thyroid 2004; 14:610.</a></li><li><a class="nounderline abstract_t">Kämpe O, Jansson R, Karlsson FA. Effects of L-thyroxine and iodide on the development of autoimmune postpartum thyroiditis. J Clin Endocrinol Metab 1990; 70:1014.</a></li><li><a class="nounderline abstract_t">Nøhr SB, Jørgensen A, Pedersen KM, Laurberg P. Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe? J Clin Endocrinol Metab 2000; 85:3191.</a></li><li><a class="nounderline abstract_t">Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid 2007; 17:609.</a></li><li><a class="nounderline abstract_t">Negro R, Greco G, Mangieri T, et al. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab 2007; 92:1263.</a></li><li><a class="nounderline abstract_t">Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002; 21:85.</a></li><li><a class="nounderline abstract_t">Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000; 343:118.</a></li><li><a class="nounderline abstract_t">Premawardhana LD, Parkes AB, Ammari F, et al. Postpartum thyroiditis and long-term thyroid status: prognostic influence of thyroid peroxidase antibodies and ultrasound echogenicity. J Clin Endocrinol Metab 2000; 85:71.</a></li></ol></div><div id="topicVersionRevision">Topic 7831 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253317" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thyroiditis after pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839259" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of postpartum thyroid dysfunction: a quantitative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869843" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312089" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Approach to the patient with postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056690" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566640" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Postpartum thyroiditis in women with hypothyroidism antedating pregnancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131598" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The occurrence of permanent thyroid failure in patients with subclinical postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3162458" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long term follow-up and HLA association in patients with postpartum hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364561" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A long-term follow-up of postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492979" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190974" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219408" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical aspects of recurrent postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20184598" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Postpartum thyroid dysfunction and the long-term risk of hypothyroidism: results from a 12-year follow-up study of women with and without postpartum thyroid dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16279852" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Postpartum thyroiditis: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2108037" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Postpartum thyroid dysfunction and HLA status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740500" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8758046" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The clinical spectrum of postpartum thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1515829" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association between postpartum thyroid dysfunction and thyroid antibodies and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2004478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thyroid disease in relation to pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583309" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Postpartum thyroid dysfunction: clinical assessment and relationship to psychiatric affective morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895224" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Postpartum thyroid dysfunction and postpartum depression: are they two linked disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2806706" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Decrease in neonatal suckled milk volume in diabetic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196025" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : How common is postpartum thyroiditis? A methodologic overview of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8379527" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Postpartum thyroiditis. A clinical, histologic, and immunopathologic study of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24400892" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100069" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7648244" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Peripartum hypopituitarism and lymphocytic hypophysitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539059" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pregnancy, postpartum autoimmune thyroiditis, and autoimmune hypophysitis: intimate relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344171" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Distinct radiological and clinical appearance of lymphocytic hypophysitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372667" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Therapeutic controversy: Screening for postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15320974" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Thyroid peroxidase antibodies in early pregnancy: utility for prediction of postpartum thyroid dysfunction and implications for screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2318931" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of L-thyroxine and iodide on the development of autoimmune postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999807" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17696828" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284630" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044345" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Excretion of antihypertensive medication into human breast milk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10891521" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Drug therapy for breast-feeding women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634366" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postpartum thyroiditis and long-term thyroid status: prognostic influence of thyroid peroxidase antibodies and ultrasound echogenicity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
